Clinical Trial Update: Study to Assess the Incidence of Local Oropharyngeal and Laryngeal Adverse Effects of Advair DISKUS 250/50 mcg BID [Phase 4]

View source ↗

Summary

Phase 4 trial update evaluating the incidence of local adverse effects in the oropharyngeal and laryngeal region with Advair DISKUS 250/50 mcg BID.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma

Drugs mentioned

• ADVAIR DISKUS (fluticasone propionate and salmeterol)

Snippet

Sponsor: Allergy & Asthma Medical Group & Research Center | Conditions: Asthma, Candidiasis, Oral | Phase 4 | Status: COMPLETED